Victoria Socha

DocwireNews

Spring Clinical Meetings 2021Tolvaptan has been approved by the FDA for use in patients with autosomal dominant polycystic kidney disease (ADPKD) to slow decline in glomerular filtration rate (GFR), increasing the therapeutic options for treatment of patients with the genetic kidney disease. Initiation of tolvaptan is time and resource intensive for patients and their healthcare providers. Kaiser Permanente Northern California (KPNC) established a virtual ADPKD nephrology panel to provide comprehensive care to patients with <a href="https://www.docwirenews.com/nephtimes/nephtimes-conferences/nephtimes-spring-clinical-meetings-nkf/healthcare-costs-higher-in-patients-with-adpkd-and-advanced-renal-dysfunction/">ADPKD</a>.During a virtual poster session at the NKF 2021 Spring Clinical Meetings, Lin Duong, PharmD described a model designed to leverage regional specialists to provide care for ADPKD patients spanning 15 service areas. The <a href="https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/abstracts?abstractId=2077">poster</a> was titled Implementing a Virtual Nephrology Panel for Tolvaptan Use in Patients with ADPKD.Beginning in 2019, a panel that included nephrologists and pharmacists met virtually every month to review consults for initiation of tolvaptan. The panel checked for complete work up, performed chart review, and screened candidacy criteria to establish recommendations. The patients were screened based on US expert guidelines.Upon initiation of tolvaptan, the patients also meet virtually with the panel pharmacist who reviews and assists with risk evaluation and mitigation strategy, education, and monitoring of adverse effects and status reports. The pharmacist also works with local nephrologists to monitor for laboratory trends and dose changes. Electronic medical records provide updates to the panel. The panel also reviews complex issues such as extra-renal manifestations of ADPKD.As of the publication of the poster, the panel had screened 34 cases. Nine of the patients initiated tolvaptan; three of those patients subsequently discontinued use. Doses were up-titrated as allowed by patient tolerance and laboratory results. Dose decreases or discontinuations were related to increases in sodium or glomerular filtration rate, liver function test, abdominal pain, or aquaretic side effects. To date, no major adverse effects have occurred. The monthly check-ins by the pharmacist in tandem with local nephrologists has ensured consistent education, care, and monitoring by the ADPKD panel.In conclusion, the author said, &ldquo;The virtual ADPKD panel provides specialized knowledge and ongoing carefully monitored care. The workflow can work for any KPNC service area and provides a seamless resource to local physicians and patients. Moreover, dedicated pharmacy support in the ADPKD panel augments patient care.&rdquo;Source: Duong L. Implementing a virtual nephrology panel for tolvaptan use in patients with ADPKD. Abstract of a poster presented at the National Kidney Foundation virtual Spring Clinical Meetings 2021 (Abstract #305), April 9, 2021.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Virtual Nephrology Panel to Monitor Tolvaptan Use in Patients with ADPKD

ADPKD

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe